A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; PL MLP (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Lipomedix Pharmaceuticals
- 29 Mar 2019 According to the Lipomedix Pharmaceuticals media release, data from 72 patients with colorectal cancer within a phase 1A-B study will be presented at the American Association for Cancer Research (AACR) annual meetin 2019.
- 31 Aug 2018 Biomarkers information updated
- 09 Jul 2018 Status changed from active, no longer recruiting to completed.